Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • InderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Bolag under bevakning
    • Teamet
Regulatoriskt pressmeddelande

Bulletin from the Extraordinary General Meeting of Chordate Medical Holding AB (publ)

Chordate Medical Holding
Ladda ner börsmeddelandet

At the Extraordinary General Meeting of Chordate Medical Holding AB (publ), held on December 8, 2025, the following resolution was passed. All resolutions were adopted in accordance with the proposals previously made public in the notice to attend the meeting.

Resolution on liquidation
The General Meeting resolved, in accordance with the Board of Directors’ proposal, that the Company shall enter into voluntary liquidation pursuant to Chapter 25, Section 3 of the Swedish Companies Act.

Attorney Lars-Olof Svensson, CMS Wistrand Advokatbyrå, was appointed liquidator.

The liquidation will enter into force when the Swedish Companies Registration Office has formally appointed the liquidator.

Resolution on delisting from Nasdaq First North Growth Market
The General Meeting resolved, in accordance with the Board of Directors’ proposal, that the shares of Chordate Medical Holding AB (publ) shall be delisted from Nasdaq First North Growth Market pursuant to item II.1.B of the Rules on Delisting at the Initiative of the Issuer issued by the Swedish Securities Council’s Self-Regulation Committee.

It was noted that the resolution on delisting was supported by shareholders representing all (100 per cent) of both the votes cast and the shares represented at the General Meeting.

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Bergs Securities AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments
Bulletin from the Extraordinary General Meeting of Chordate Medical Holding AB (publ)

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.